0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.

      Cancer research
      Antineoplastic Agents, therapeutic use, Apoptosis, drug effects, Breast Neoplasms, drug therapy, metabolism, pathology, Drug Resistance, Neoplasm, Gene Expression Profiling, Humans, Immunoblotting, Kinesin, genetics, Oligonucleotide Array Sequence Analysis, RNA, Messenger, Reverse Transcriptase Polymerase Chain Reaction, Taxoids, Tubulin, Tumor Cells, Cultured, Tumor Markers, Biological

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resistance to chemotherapy remains a major barrier to the successful treatment of cancer. To understand mechanisms underlying docetaxel resistance in breast cancer, we used an insertional mutagenesis strategy to identify proteins whose overexpression confers resistance. A strong promoter was inserted approximately randomly into the genomes of tumor-derived breast cancer cells, using a novel lentiviral vector. We isolated a docetaxel-resistant clone in which the level of the kinesin KIFC3 was elevated. When KIFC3 or the additional kinesins KIFC1, KIF1A, or KIF5A were overexpressed in the breast cancer cell lines MDA-MB231 and MDA-MB 468, the cells became more resistant to docetaxel. The binding of kinesins to microtubules opposes the stabilizing effect of docetaxel that prevents cytokinesis and leads to apoptosis. Our finding that kinesins can mediate docetaxel resistance might lead to novel therapeutic approaches in which kinesin inhibitors are paired with taxanes.

          Related collections

          Author and article information

          Comments

          Comment on this article